Adaptive Biotechnologies (NASDAQ:ADPT) Sees Unusually-High Trading Volume – What’s Next?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares saw unusually-strong trading volume on Friday . Approximately 913,268 shares traded hands during mid-day trading, an increase of 50% from the previous session’s volume of 610,285 shares.The stock last traded at $22.43 and had previously closed at $22.10.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Guggenheim lifted their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, June 29th. TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Wednesday. BTIG Research reaffirmed a “buy” rating and issued a $22.00 target price on shares of Adaptive Biotechnologies in a research report on Wednesday, June 17th. JPMorgan Chase & Co. cut their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.83.

Adaptive Biotechnologies Stock Performance

The stock has a market cap of $3.62 billion, a price-to-earnings ratio of -68.48 and a beta of 2.07. The company’s 50 day simple moving average is $17.41 and its 200 day simple moving average is $16.17.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.20) earnings per share. Sell-side analysts predict that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Insider Transactions at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Francis Lo sold 51,004 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $22.45, for a total value of $1,145,039.80. Following the sale, the insider directly owned 237,688 shares in the company, valued at approximately $5,336,095.60. The trade was a 17.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harlan S. Robins sold 386,240 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $22.01, for a total transaction of $8,501,142.40. Following the transaction, the insider owned 1,019,658 shares of the company’s stock, valued at approximately $22,442,672.58. This trade represents a 27.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 920,545 shares of company stock valued at $18,588,281 in the last three months. 5.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Adaptive Biotechnologies

Large investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth $28,000. EverSource Wealth Advisors LLC raised its holdings in Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after buying an additional 1,565 shares during the period. KBC Group NV purchased a new stake in Adaptive Biotechnologies during the first quarter valued at about $45,000. Assetmark Inc. boosted its holdings in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after buying an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies in the fourth quarter worth approximately $51,000. 99.17% of the stock is owned by institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.